I would not say that we don't have the "manufacturing needed for COVID", we just don't have the number of vials needed on hand to treat everyone. We have significant capacity and quality manufacturers in AGC and Samsung. As a company Cytodyn lacks a reason and funds to accelerate manufacturing efforts. FDA approval or some accelerated approval process would be our reason, funding would fall into place, whether it be grants or more traditional financing. I still think we lack enough data to please the FDA and receive emergency approval, but I'm not a data scientist only going off what I've seen in the past.